Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Deferred Tax (2016 - 2025)

United Therapeutics' Long-Term Deferred Tax history spans 17 years, with the latest figure at $357.7 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 21.97% year-over-year to $357.7 million; the TTM value through Dec 2025 reached $357.7 million, down 21.97%, while the annual FY2025 figure was $357.7 million, 21.97% down from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $357.7 million at United Therapeutics, up from $354.9 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $458.4 million in Q4 2024 and bottomed at $261.9 million in Q4 2021.
  • The 5-year median for Long-Term Deferred Tax is $326.6 million (2022), against an average of $342.7 million.
  • The largest annual shift saw Long-Term Deferred Tax rose 25.12% in 2022 before it dropped 21.97% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $261.9 million in 2021, then increased by 25.12% to $327.7 million in 2022, then rose by 20.48% to $394.8 million in 2023, then increased by 16.11% to $458.4 million in 2024, then decreased by 21.97% to $357.7 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Long-Term Deferred Tax are $357.7 million (Q4 2025), $354.9 million (Q3 2025), and $456.2 million (Q2 2025).